Cingulate Inc. (CING) earnings
CING earnings moved a median of -2.00% by the close. Quarterly and annual CING reports and results, each read against the price at its own news timestamp. Back to the CING overview →
22 measured CING earnings events.
Where these CING earnings landedvs 19 measured CING earnings reactions
| Middle 50% of CING earnings reactions | -6.31% to +0.60% |
|---|---|
| Median reaction (to close) | -2.00% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 CING earnings events with a measured close landed between -6.31% and +0.60%; 32% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness | Press release | +1.46% | +0.60% | |
| Form 10-Q Cingulate Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.46% | +0.60% | |
| Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301 | Press release | +0.47% | -6.79% | |
| Form 10-Q Cingulate Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.47% | -6.79% | |
| Form 10-K Cingulate Inc. For: Dec 31 | SEC filing · Form 10-K | -3.36% | -27.04% | |
| Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -2.91% | — | |
| Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights | Press release | -0.12% | — | |
| Form 10-Q Cingulate Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.12% | — | |
| Form NT 10-Q Cingulate Inc. For: Jun 30 | SEC filing · Form NT | -3.85% | -5.83% | |
| Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets | Press release | +0.00% | -0.74% | |
| Form 10-Q Cingulate Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -0.74% | |
| Form 10-K Cingulate Inc. For: Dec 31 | SEC filing · Form 10-K | -2.74% | +3.08% | |
| Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved | Press release | -1.22% | +3.57% | |
| Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market | Press release | -5.75% | +4.24% | |
| Form 10-Q Cingulate Inc. For: Sep 30 | SEC filing · Form 10-Q | -5.75% | +4.24% | |
| Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved | Press release | -10.58% | -23.21% | |
| Form 10-Q Cingulate Inc. For: Jun 30 | SEC filing · Form 10-Q | -10.58% | -23.21% | |
| Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update | Press release | -0.66% | -2.00% | |
| Form 10-Q Cingulate Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.66% | -2.00% | |
| Form 10-K Cingulate Inc. For: Dec 31 | SEC filing · Form 10-K | +1.80% | -1.80% | |
| Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update | Press release | +0.00% | -3.23% | |
| Form 10-Q Cingulate Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -3.23% |
Keep exploring
More CING: analyst actions → · SEC filings → · CING overview →